New Generation of Molecular Prognostic and Predictive Tests for Breast Cancer

Seminars in Oncology

Volumn 34, Issue SUPPL. 3, 2007, Pages

  Pusztai, Lajos ^a   Cristofanilli, Massimo ^a   Paik, Soonmyung ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; BREAST CANCER; DIAGNOSTIC KIT; DIAGNOSTIC TEST; GENOME ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TREATMENT RESPONSE; TUMOR CELL;

BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; PROGNOSIS; RECEPTORS, ESTROGEN; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34249095430     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2007.03.015     Document Type: Article

References (27)

1. Ravdin P.M., Siminoff I.A., and Harvey J.A. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 16 (1998) 515-521
2. Bast Jr. R.C., Ravdin P., Hayes D.F., et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19 (2001) 1865-1878
3. van 't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
4. van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 (2002) 1999-2009
5. Buyse M., Loi S., van't Veer L., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98 (2006) 1183-1192
6. Wang Y., Klijn J.G., Zhang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 (2005) 671-679
7. Foekens J.A., Atkins D., Zhang Y., et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 24 (2006) 1665-1671
8. Bonneterre J., Thurlimann B., Robertson J.F., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18 (2000) 3748-3757
9. Rhodes A., Jasani B., Barnes D.M., et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 53 (2000) 125-130
10. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004) 2817-2826
11. Habel L.A., Shak S., Jacobs M.K., et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 8 (2006) R25
12. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24 (2006) 3726-3734
13. Fisher B., Bryant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16 (1998) 2672-2685
14. M. D. Anderson Cancer Center: Chemotherapy Response Calculators. Available at: http://www.mdanderson.org/care_centers/breastcenter/dIndex.cfm?pn=448442 B2-3EA5-4BAC-98310076A9553E63 (accessed November 1, 2006)
15. Rouzier R., Pusztai L., Delaloge S., et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 23 (2005) 8331-8339
16. Di Leo A., and Isola J. Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: Are we at the end of the beginning?. Clin Breast Cancer 4 (2003) 179-186
17. Pusztai L., and Gianni L. Technology insight: Emerging techniques to predict response to preoperative chemotherapy in breast cancer. Nat Clin Pract Oncol 1 (2004) 44-50
18. Hess K.R., Anderson K., Symmans W.F., et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24 (2006) 4236-4244
19. Ashworth T. A case of cancer in which cells similar to those in the tumors were seen in the blood after death. Med J Aust 14 (1869) 146
20. Kagan M., Howard D., Bendele T., et al. A sample preparation and analysis system for identification of circulating tumor cells. J Clin Ligand Assay 25 (2002) 104-110
21. Cristofanilli M., Budd G.T., Ellis M.J., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351 (2004) 781-791
22. Cristofanilli M. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Semin Oncol 33 suppl (2006) S9-S14
23. Cristofanilli M., Hayes D.F., Budd G.T., et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23 (2005) 1420-1430
24. Kattan M.W. Evaluating a new marker's predictive contribution. Clin Cancer Res 10 (2004) 822-824
25. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 23 (2005) 7332-7341
26. US Food and Drug Administration. Center for Devices and Radiologic Health homepage. Available at: www.fda.gov/cdrh (accessed November 1, 2006)
27. US Food and Drug Administration. Draft guidance for industry, clinical laboratories, and FDA staff on in vitro diagnostic multivariate index assays; Availability. Available at: www.fda.gov/OHRMS/DOCKETS/98fr/ch0641.pdf (accessed November 1, 2006)